Review Articles
A practical guide to the interpretation of PK/PD profiles of longer-acting analogue insulins. Part one: The principles of glucose clamp studies
Submitted: 24 October 2019 | Published: 12 July 2018
About the author(s)
Oppel B.W. Greeff, University of Pretoria, South AfricaJacob John van Tonder, Triclinium Clinical Development (Pty) Ltd, South Africa
Kershlin Naidu, Chris Hani Baragwanath Academic Hospital, University of the Witwatersrand, South Africa
Alicia McMaster, Sanofi-Aventis South Africa (Pty) Ltd, South Africa
Alet van Tonder, Sanofi-Aventis South Africa (Pty) Ltd, South Africa
Rashem Mothilal, Sanofi-Aventis South Africa (Pty) Ltd, South Africa
Full Text:
PDF (189KB)Abstract
Glucose clamp studies are used to determine pharmacokinetics (PK) and pharmacodynamics (PD) of analogue insulins. With the development of longer-acting basal analogue insulins, including glargine 300 (Gla-300) and insulin degludec (IDeg), results from numerous glucose clamp studies are readily available. However, interpreting PK/PD profiles in a scientifically sound manner can be a challenging feat. This is the first in a series of publications that will suggest practical tips for interpreting and comparing results from glucose clamp studies. Variations in the glucose clamp methodology, duration of clamp studies and glucose clamp targets influence the study design and results significantly. Selection of study populations, including healthy patients or patients with Type 1 or 2 diabetes mellitus, has important implications. The dose of study insulin should reflect that of the general treatment population, and ideally steady-state conditions should be used. During the study the plasma insulin concentration and glucose infusion rate describe the pharmacokinetics and pharmacodynamics of the study insulin. With these practical tips in mind, results of glucose clamp studies can be interpreted in a scientifically correct manner. The next article in this series will discuss the interpretation of PK/PD profiles using two newly developed longer-acting basal analogue insulins: Gla-300 and IDeg.
Keywords
Metrics
Total abstract views: 2180Total article views: 587